Clinical trials: HPV Vaccines
Cervical Cancer, Genital Wart
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45…
- Conditions
- Cervical Cancer, Genital Wart, CIN1, CIN2
- Trial name
- NCT05584332
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- China
- Volunteers
- 3,131 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
High Grade Cervical Intraepithelial Neoplasia
An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)
This is an exploratory, open, prospective multi-centre study of VB10.16 immunotherapy in patients with high grade HPV16+ Cervical Intraepithelial Neoplasia (HSIL; CIN2/3).
- Trial name
- NCT02529930
- Testing
- VB10.16 Immunotherapy (DNA vaccine)
- Where
- 4 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Nykode Therapeutics ASA
Vaccine Refusal, Vaccine Hesitancy
Active Health Education to Increase HPV Vaccine Coverage in Youth: A Stepped-wedge, Cluster, and Randomized Trial
This study aims to evaluate the impact of active health education methodologies on increasing adherence to the HPV vaccine among schoolchildren.
- Trial name
- EDUCAVAC (NCT06513494)
- Testing
- Active Students Education plus Teacher Training, Active Students Education, Basic Health Unit Active Orientation
- Where
- 79 sites in Brazil
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Hospital Israelita Albert Einstein
HPV Immunization Status
Strengthening Physician Communication About HPV Vaccines
The purpose of this study is to determine if a multimodal Human Papillomavirus (HPV) immunization program carried out in pediatric and family medicine practices would be more effective in improving adolescent patients' HPV…
- Trial name
- NCT02456077
- Testing
- Multimodal Vaccine Program
- Where
- United States
- Volunteers
- 93,582 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Human Papillomavirus Infection
A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine
This Study to Evaluate the Immunogenicity and Safety of Candidate Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli) Administered Intramuscularly in Healthy Female…
- Trial name
- NCT06207175
- Testing
- Nonavalent HPV study vaccine, GARDASIL® 9
- Where
- Indonesia
- Volunteers
- 1,260 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Dose Schedule Study
Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil
To demonstrate that Gardasil® vaccine, when given to girls 11-13 years of age according to 1 of 3 alternative 3-dose schedules (0, 3, 9 months; 0, 6, 12 months; or 0, 12, 24 months), results in anti-HPV type 16 and anti-HPV type…
- Trial name
- NCT00524745
- Testing
- Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
- Where
- Vietnam
- Volunteers
- 903 people, healthy volunteers welcome
- Sponsor
- PATH
Chronic Kidney Diseases, Kidney Transplant
Immunogenicity of HPV Vaccine in Transplant Recipients.
To measure levels of HPV antibodies in post-solid-organ transplant recipients who have gotten the HPV9 vaccine.
- Trial name
- NCT05557370
- Testing
- Human Papilloma Virus vaccine (GARDASIL 9)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Papillomavirus Infections
V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)
This study aims to demonstrate that a 2-dose regimen of the 9-Valent Human Papillomavirus (9vHPV) vaccine (GARDASIL™9, V503) induces non-inferior competitive Luminex immunoassay (cLIA) geometric mean titers (GMTs) to each of the…
- Trial name
- NCT05450705
- Testing
- 9vHPV vaccine
- Where
- 2 sites in China
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papillomavirus Infections
The KEN SHE Study on HPV-vaccine Efficacy
The KEN SHE Study aims to identify effective cervical cancer prevention strategies. Cervical cancer is caused by an infection with Human Papillomavirus, also called HPV.
- Trial name
- NCT03675256
- Testing
- immediate Gardasil 9, delayed MenVeo vaccine, immediate MenVeo vaccine, delayed Gardasil 9, immediate Cervarix, delayed MenVeo vaccine
- Where
- 3 sites in Kenya
- Volunteers
- 2,275 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Cervical Cancer, Genital Wart
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
This study will evaluate the immunogenicity and safety of Zerun 9-valent HPV recombinant vaccine in healthy female 16-26 years of age by comparing with GARDASIL®9.
- Conditions
- Cervical Cancer, Genital Wart, CIN, VIN
- Trial name
- NCT05580341
- Testing
- Zerun HPV-9, GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
HPV Vaccine Acceptability
A Health Belief Model Based Intervention to Increase Human Papilloma Virus (HPV) Vaccination Among College Men
The purposes of this study are to (1) identify predictors of Human papillomavirus (HPV) vaccine acceptability among college men based on the Health Belief Model through focus groups, (2) triangulate focus group results with a…
- Trial name
- NCT01431079
- Testing
- HPV vaccine acceptability
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
Vaccines
HPV Centralized R/R RCT #2 - New York State
The work done in this trial builds off of the work previously conducted by this same research group in clinicaltrials.gov ID: NCT03057379.
- Trial name
- NCT03294551
- Testing
- HPV Vaccine Reminder Recall - Autodialer, HPV Vaccine Reminder Recall - Texting
- Where
- United States
- Volunteers
- 37,003 people
- Sponsor
- University of California, Los Angeles
HPV Vaccine Knowledge
Health Beliefs, Behaviors, and Healthcare Experiences Among United States Young and Mid-Age Adults
The study will provide important insight into current HPV vaccine knowledge/awareness, health beliefs, affect, vaccine discussions, decision preparedness, and vaccine intentions and behaviors among those ages 18-45, while…
- Trial name
- NCT04766164
- Testing
- Survey
- Where
- United States
- Volunteers
- 4,000 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Vaccine Refusal
Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for AfAm Adolescents in Alabama
In this 30-month study, the investigators propose to develop a culturally appropriate vaccine confidence intervention, targeting positive change related to HPV vaccine uptake behavior and reducing sentiments of hesitancy towards…
- Trial name
- NCT04604743
- Testing
- Intervention, TBN
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Human Papilloma Virus Vaccines, Attitude to Health
An Evaluation of Tailored Messages to Address Parental Questions About HPV Vaccination
The purpose of this study is to investigate mother's attitudes about vaccinating their 11-14 year old children against the human papillomavirus (HPV).
- Trial name
- NCT03628885
- Testing
- Top Concern Tailored Intervention, All Concerns Tailored Intervention
- Where
- United States
- Volunteers
- 908 people, healthy volunteers welcome
- Sponsor
- Indiana University
Human Papilloma Virus, HPV
Acceptance of Human Papillomavirus Vaccination in Postpartum Women
Worldwide cervical cancer remains a major cause mortality among women. It is estimated that each year over 490,000 women are diagnosed with cervical cancer and more than 270,000 die from the disease.
- Conditions
- Human Papilloma Virus, HPV, Post Partum
- Trial name
- HPV Acceptance (NCT00730704)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Columbia University
HPV-Related Squamous Cell Carcinoma
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 \& HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts…
- Trial name
- NCT04180215
- Testing
- HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab.
- Where
- 34 sites in United States, Netherlands and 1 more
- Volunteers
- 198 people
- Sponsor
- Hookipa Biotech GmbH
Warts, Human Papilloma Virus
Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy
- Trial name
- NCT05291845
- Testing
- Candida antigen vaccine, Bivalent HPV vaccine
- Where
- Egypt
- Volunteers
- 162 people
- Sponsor
- Zagazig University
Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm
ESCUDDO Long Term Follow Up
This phase IV trial evaluates the long term protection provided by either one or two doses of the 9v human papillomavirus (HPV) vaccine for participants who were part of the ESCUDDO study.
- Trial name
- ESCUDDO LTFU (NCT07706673)
- Testing
- Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Recombinant Human Papillomavirus Nonavalent Vaccine
- Where
- Costa Rica
- Volunteers
- 13,700 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
Discovery of HPV T Cell Epitopes and Development of Multi-epitope Vaccines
Based on the trend that the incidence and mortality of cervical carcinoma among female cancers worldwide are increasing year by year, the investigators aim to develop a multi-epitope therapeutic vaccine capable of simultaneously…
- Trial name
- NCT07077980
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Anhui Provincial Hospital